DexCom, Inc. (DXCM) Stake Decreased by Teachers Advisors LLC
Teachers Advisors LLC lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 30.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 96,562 shares of the medical device company’s stock after selling 41,363 shares during the quarter. Teachers Advisors LLC owned about 0.11% of DexCom worth $7,064,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of DexCom during the 1st quarter worth approximately $164,000. Brighton Jones LLC purchased a new stake in shares of DexCom during the 1st quarter worth approximately $204,000. IFP Advisors Inc lifted its position in shares of DexCom by 30.5% during the 2nd quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after buying an additional 568 shares during the last quarter. Independent Portfolio Consultants Inc. lifted its position in shares of DexCom by 0.4% during the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after buying an additional 9 shares during the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in shares of DexCom by 9.2% during the 2nd quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock worth $216,000 after buying an additional 250 shares during the last quarter.
In other DexCom news, EVP Andrew K. Balo sold 3,200 shares of the business’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $71.55, for a total value of $228,960.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $69.34, for a total transaction of $416,040.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,223 shares of company stock worth $2,285,138. 1.70% of the stock is owned by company insiders.
DexCom, Inc. (NASDAQ DXCM) opened at 47.74 on Friday. The stock’s 50 day moving average is $67.67 and its 200-day moving average is $72.02. DexCom, Inc. has a 1-year low of $42.62 and a 1-year high of $88.80. The firm’s market capitalization is $4.13 billion.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The business had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. During the same period in the previous year, the business earned ($0.24) earnings per share. The company’s revenue was up 24.3% on a year-over-year basis. Equities research analysts forecast that DexCom, Inc. will post ($0.80) EPS for the current year.
DXCM has been the subject of several recent analyst reports. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Cowen and Company restated a “buy” rating and set a $90.00 price objective on shares of DexCom in a research report on Friday, July 14th. BMO Capital Markets restated a “buy” rating and set a $105.00 price objective on shares of DexCom in a research report on Thursday, July 13th. Piper Jaffray Companies restated a “buy” rating and set a $78.00 price objective on shares of DexCom in a research report on Wednesday, July 12th. Finally, Oppenheimer Holdings, Inc. set a $92.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. One analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company’s stock. DexCom presently has a consensus rating of “Buy” and a consensus target price of $72.19.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Stock Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related stocks with our FREE daily email newsletter.